Current Zepbound injection safety guide

Zepbound injection side effects: current rates and warning signs

Review common Zepbound injection side effects, current label rates, serious warning signs, hydration and glucose questions, and compounded-tirzepatide distinctions.

Educational guideUpdated August 8, 2026

A label-first Zepbound injection side-effect check

Confirm the exact product and presentation: FDA-approved Zepbound pen, vial, or KwikPen rather than Mounjaro, compounded tirzepatide, or an unverified product.

Describe each symptom, when it began, severity, recurrence, food and fluid intake, urine output, glucose readings when relevant, and any refill or clinician-directed treatment change.

Separate common digestive or local reactions from severe abdominal pain, dehydration, low blood sugar, gallbladder, allergy, thyroid, or procedure warning signs.

Share insulin, sulfonylureas, kidney or stomach-emptying history, pregnancy plans, oral medicines, and upcoming anesthesia or deep sedation.

Contact the responsible prescriber before skipping, repeating, stopping, restarting, or changing treatment; use urgent care for serious warning signs.

Direct answer

The current Zepbound label lists nausea, diarrhea, vomiting, constipation, abdominal pain, indigestion, injection-site reactions, fatigue, hypersensitivity reactions, belching, hair loss, reflux, gas, abdominal bloating, dizziness, and low blood pressure among reactions reported in at least 2% of treated adults and more often than with placebo in two pooled weight-reduction trials. Nausea was reported in 25%, 29%, and 28% of the 5 mg, 10 mg, and 15 mg groups, respectively, versus 8% with placebo. These are product-, dose-group-, and study-specific rates—not a prediction for one patient, Mounjaro, or compounded tirzepatide. Contact the prescriber for persistent, worsening, recurrent, or treatment-limiting symptoms. Severe or persistent abdominal pain, repeated vomiting or inability to keep fluids down, markedly reduced urination, fainting or confusion, jaundice, facial or throat swelling, trouble breathing, or a neck mass with swallowing difficulty needs prompt in-person or emergency assessment.

Common adverse reactions

The current Zepbound table reports dose-group-specific digestive rates

The current Eli Lilly Zepbound prescribing information was updated April 22, 2026. In two pooled placebo-controlled adult weight-reduction trials, nausea occurred in 8% with placebo and 25%, 29%, and 28% with Zepbound 5 mg, 10 mg, and 15 mg. The corresponding rates were 8%, 19%, 21%, and 23% for grouped diarrhea or frequent bowel movements; 2%, 8%, 11%, and 13% for vomiting; 5%, 17%, 14%, and 11% for grouped constipation or hard stool; 5%, 9%, 9%, and 10% for grouped abdominal pain; and 4%, 9%, 9%, and 10% for indigestion. These comparisons describe trial groups and do not prove the cause, severity, or expected duration of one person’s symptom.

Keep each percentage tied to the labeled adult weight-reduction trial group; do not add dose-group rates together or treat them as an individual forecast.
The grouped diarrhea, constipation, and abdominal-pain rows combine related terms, so they are not rates for one exact symptom presentation.
Report symptoms that are persistent, recurrent, worsening, severe, intake-limiting, or disruptive even when they appear in the common-reaction table.

Other labeled reactions

Local reactions, fatigue, allergy, reflux, hair loss, dizziness, and low blood pressure also appear in the table

The same pooled table reports injection-site reactions in 6%, 8%, and 8% of the Zepbound groups versus 2% with placebo; grouped fatigue in 5%, 6%, and 7% versus 3%; hypersensitivity reactions in 5% across the three groups versus 3%; and hair loss in 5%, 4%, and 5% versus 1%. Belching, reflux, gas, abdominal bloating, dizziness, and grouped low-blood-pressure reactions also met the table threshold in one or more Zepbound groups. These categories have definitions and evidence limits: for example, injection-site reactions combine several local symptoms, and the fatigue category includes asthenia, lethargy, and malaise.

Do not present a grouped reaction percentage as a burning-only, redness-only, itching-only, hair-shedding-pattern, or fatigue-severity rate.
A symptom after an injection can also reflect illness, dehydration, another medicine, reduced intake, a skin exposure, or a different condition that needs review.
Whole-body allergy symptoms, spreading local symptoms, severe weakness, fainting, or other serious changes need escalation rather than a trial-rate comparison.

Digestive effects, hydration, and glucose

Treatment-phase patterns do not create a universal waiting period

The label says most nausea, vomiting, and diarrhea events occurred during clinician-directed dose escalation and decreased over time in the pooled weight-reduction trials. That group-level pattern does not establish one start date, duration, or safe period to wait. Zepbound labeling warns about acute kidney injury due to volume depletion. It also warns that low-blood-sugar risk can increase with insulin or an insulin secretagogue such as a sulfonylurea, while hypoglycemia has also been associated with Zepbound in adults without type 2 diabetes.

Record vomiting or diarrhea episodes, bowel pattern, the ability to keep fluids and food down, urine amount and color, dizziness, fainting, weakness, and recent illness or heat exposure.
If glucose monitoring is part of care, record readings with symptoms, meals, activity, alcohol, insulin, sulfonylureas, and other glucose-lowering medicines.
Do not improvise a treatment hold, catch-up injection, restart, anti-nausea medicine, laxative, hydration recipe, or glucose plan from generic online advice.

Serious label warnings

Common stomach symptoms should not obscure abdominal, allergy, thyroid, or procedure warning signs

Current Zepbound labeling includes a boxed warning about thyroid C-cell tumors observed in rats; it is unknown whether tirzepatide causes these tumors in humans. Zepbound is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2. The label also addresses acute pancreatitis, gallbladder disease, severe gastrointestinal reactions, kidney injury from volume depletion, serious hypersensitivity, diabetic-retinopathy complications in patients with type 2 diabetes, and pulmonary aspiration during general anesthesia or deep sedation. A page cannot diagnose these conditions or replace an examination.

Seek prompt care for severe or persistent abdominal pain, especially pain that may spread to the back, with or without nausea or vomiting; jaundice, fever, or right-upper-abdominal pain also needs assessment.
Trouble breathing or swallowing, facial or throat swelling, fainting, widespread hives, a neck mass, persistent hoarseness, or rapidly developing serious symptoms requires urgent or emergency evaluation.
Tell the procedure and anesthesia team about the exact product, symptoms, and treatment timing; do not create a self-directed hold or restart schedule.

Product identity and compounded care

Zepbound rates do not automatically apply to Mounjaro or compounded tirzepatide

Zepbound is an FDA-approved Eli Lilly tirzepatide injection with product-specific chronic-weight-management and obstructive-sleep-apnea indications for adults. Current labeling includes single-dose pens and vials, multi-dose vials, and single-patient-use KwikPens. Mounjaro contains tirzepatide but has different indications, study populations, presentations, and adverse-reaction tables. A patient-specific compounded tirzepatide injection is not an FDA-approved Zepbound or Mounjaro finished product and is not an FDA-approved generic tirzepatide. It may differ in concentration, inactive ingredients, container, supplies, labeling, storage, and beyond-use date.

Preserve the exact product, presentation, prescription and pharmacy label, refill or lot details, storage history, and a photo of the current package.
Do not transfer Zepbound percentages, presentation instructions, or storage rules to Mounjaro, a compounded vial, a research-use product, or an unlabeled injection.
Avoid no-prescription sellers, counterfeit pens, unlabeled mixtures, copied syringe charts, and claims that stronger side effects prove potency or better results.

Patient safety checklist

Questions to ask about possible Zepbound injection side effects

These points are educational and do not replace medical advice. A licensed clinician should review individual history, medications, risks, and state-specific availability before treatment.

✓

Is the product authentic FDA-approved Zepbound, and which pen, vial, or KwikPen presentation and labeled indication apply?

✓

Which symptoms occurred, when did they begin, how severe are they, and are they stable, improving, worsening, recurring, or limiting normal activity?

✓

Can I keep fluids and food down, how often am I urinating, and do I have repeated vomiting, diarrhea, constipation, dizziness, fainting, fever, jaundice, or severe abdominal pain?

✓

Are there low-blood-sugar symptoms, facial or throat swelling, trouble breathing, rash, a neck mass, persistent hoarseness, or difficulty swallowing?

✓

Did symptoms follow a clinician-directed treatment change, refill, storage problem, illness, procedure, travel, diet change, alcohol use, or another medicine?

✓

Do insulin, sulfonylureas, kidney disease, diabetic retinopathy, severe stomach-emptying symptoms, pregnancy plans, oral contraceptives, or an upcoming procedure change the plan?

✓

Should the current package, refill or lot, storage history, inactive ingredients, injection supplies, or dispensing source be reviewed?

✓

Who should decide whether treatment pauses, continues, or changes, and which symptoms require same-day, urgent, or emergency care?

FAQs

Short answers for patients

What are the most common side effects of Zepbound injection?

Current Zepbound labeling lists nausea, diarrhea, vomiting, constipation, abdominal pain, indigestion, injection-site reactions, fatigue, hypersensitivity reactions, belching, hair loss, reflux, gas, abdominal bloating, dizziness, and low blood pressure among reactions reported in at least 2% of treated adults and more often than with placebo in two pooled weight-reduction trials.

How common is nausea with Zepbound?

In two pooled adult weight-reduction trials, nausea occurred in 8% of placebo participants and 25%, 29%, and 28% of participants receiving Zepbound 5 mg, 10 mg, and 15 mg, respectively. These are study-group rates, not an individual prediction.

How long do Zepbound injection side effects last?

The current label does not provide one duration for every reaction or patient. It says most nausea, vomiting, and diarrhea events occurred during dose escalation and decreased over time in the pooled trials, but that is not a promise that symptoms will be brief or safe to ignore. Contact the prescriber for persistent, recurrent, worsening, severe, or intake-limiting symptoms.

Are Zepbound injection-site side effects covered here?

This page gives a whole-product safety overview. Zepbound labeling reports a grouped injection-site-reaction category, but a persistent, spreading, unusually painful, draining, blistering, darkening, or whole-body reaction needs symptom-specific assessment. The separate Zepbound injection-site-reaction guide reviews that intent in detail.

Do Zepbound side-effect rates apply to Mounjaro?

No. Both products contain tirzepatide, but they have different labeled uses, study populations, presentations, and adverse-reaction tables. Product-specific percentages should not be transferred or compared as though the trials were head-to-head.

Do Zepbound rates apply to compounded tirzepatide?

No. A patient-specific compounded preparation is not an FDA-approved Zepbound finished product and may differ in concentration, inactive ingredients, presentation, supplies, labeling, storage, and beyond-use date. Zepbound trial percentages do not establish its side-effect incidence or quality.

Should I stop Zepbound because of side effects?

Do not skip, repeat, stop, restart, split, increase, decrease, or switch treatment based on generic online advice. Contact the responsible prescriber with the exact product and symptom pattern before the next treatment decision. Serious warning signs require prompt in-person or emergency assessment.

When are Zepbound injection side effects urgent?

Seek prompt care for severe or persistent abdominal pain, repeated vomiting, inability to keep fluids down, markedly reduced urination, fainting, confusion, jaundice, trouble breathing or swallowing, facial or throat swelling, widespread hives, a neck mass with swallowing difficulty, or rapidly worsening symptoms.

Sources and related reading

Peptide12 pages use conservative educational language and authoritative sources where possible.

DailyMed: Current ZEPBOUND prescribing information — updated April 22, 2026 DailyMed API: Manufacturer ZEPBOUND structured product label MedlinePlus: Tirzepatide injection drug information — revised February 15, 2026 MedlinePlus: Dehydration MedlinePlus: Low blood sugar FDA: Compounding and the FDA — Questions and Answers Peptide12: Zepbound Peptide12: Compounded tirzepatide injection Peptide12: Zepbound injection-site reaction Peptide12: Zepbound injection sites Peptide12: Tirzepatide nausea Peptide12: Tirzepatide constipation Peptide12: GLP-1 low blood sugar Peptide12: When to message your clinician Peptide12: How online peptide therapy works